Switch theme
Sign up to access all valuation multiples
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.
1997
20.2K+
LTM Revenue $4.4B
LTM EBITDA $1.2B
$55.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jiangsu Hengrui Pharma has a last 12-month revenue (LTM) of $4.4B and a last 12-month EBITDA of $1.2B.
In the most recent fiscal year, Jiangsu Hengrui Pharma achieved revenue of $3.9B and an EBITDA of $1.1B.
Jiangsu Hengrui Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jiangsu Hengrui Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $4.4B | XXX | $3.9B | XXX | XXX | XXX |
| Gross Profit | $3.8B | XXX | $3.4B | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | $1.2B | XXX | $1.1B | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| EBIT | $1.2B | XXX | $947M | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $1.1B | XXX | $882M | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 23% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 15, 2025, Jiangsu Hengrui Pharma's stock price is CNY 64 (or $9).
Jiangsu Hengrui Pharma has current market cap of CNY 424B (or $59.0B), and EV of CNY 400B (or $55.7B).
See Jiangsu Hengrui Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $55.7B | $59.0B | XXX | XXX | XXX | XXX | $0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 15, 2025, Jiangsu Hengrui Pharma has market cap of $59.0B and EV of $55.7B.
Jiangsu Hengrui Pharma's trades at 14.3x EV/Revenue multiple, and 50.3x EV/EBITDA.
Equity research analysts estimate Jiangsu Hengrui Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jiangsu Hengrui Pharma has a P/E ratio of 55.4x.
See valuation multiples for Jiangsu Hengrui Pharma and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $59.0B | XXX | $59.0B | XXX | XXX | XXX |
| EV (current) | $55.7B | XXX | $55.7B | XXX | XXX | XXX |
| EV/Revenue | 12.7x | XXX | 14.3x | XXX | XXX | XXX |
| EV/EBITDA | 45.8x | XXX | 50.3x | XXX | XXX | XXX |
| EV/EBIT | 47.3x | XXX | 58.8x | XXX | XXX | XXX |
| EV/Gross Profit | 14.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 55.4x | XXX | 66.9x | XXX | XXX | XXX |
| EV/FCF | 61.3x | XXX | 73.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJiangsu Hengrui Pharma's last 12 month revenue growth is 15%
Jiangsu Hengrui Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Jiangsu Hengrui Pharma's rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jiangsu Hengrui Pharma's rule of X is 65% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jiangsu Hengrui Pharma and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | 28% | XXX | XXX | XXX |
| EBITDA Growth | 17% | XXX | 33% | XXX | XXX | XXX |
| Rule of 40 | 38% | XXX | 43% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 65% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 24% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 62% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangsu Hengrui Pharma acquired XXX companies to date.
Last acquisition by Jiangsu Hengrui Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Jiangsu Hengrui Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Jiangsu Hengrui Pharma founded? | Jiangsu Hengrui Pharma was founded in 1997. |
| Where is Jiangsu Hengrui Pharma headquartered? | Jiangsu Hengrui Pharma is headquartered in China. |
| How many employees does Jiangsu Hengrui Pharma have? | As of today, Jiangsu Hengrui Pharma has 20.2K+ employees. |
| Is Jiangsu Hengrui Pharma publicy listed? | Yes, Jiangsu Hengrui Pharma is a public company listed on SHG. |
| What is the stock symbol of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma trades under 600276 ticker. |
| When did Jiangsu Hengrui Pharma go public? | Jiangsu Hengrui Pharma went public in 2000. |
| Who are competitors of Jiangsu Hengrui Pharma? | Similar companies to Jiangsu Hengrui Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma's current market cap is $59.0B |
| What is the current revenue of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma's last 12 months revenue is $4.4B. |
| What is the current revenue growth of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Jiangsu Hengrui Pharma? | Current revenue multiple of Jiangsu Hengrui Pharma is 12.7x. |
| Is Jiangsu Hengrui Pharma profitable? | Yes, Jiangsu Hengrui Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma's last 12 months EBITDA is $1.2B. |
| What is Jiangsu Hengrui Pharma's EBITDA margin? | Jiangsu Hengrui Pharma's last 12 months EBITDA margin is 28%. |
| What is the current EV/EBITDA multiple of Jiangsu Hengrui Pharma? | Current EBITDA multiple of Jiangsu Hengrui Pharma is 45.8x. |
| What is the current FCF of Jiangsu Hengrui Pharma? | Jiangsu Hengrui Pharma's last 12 months FCF is $908M. |
| What is Jiangsu Hengrui Pharma's FCF margin? | Jiangsu Hengrui Pharma's last 12 months FCF margin is 21%. |
| What is the current EV/FCF multiple of Jiangsu Hengrui Pharma? | Current FCF multiple of Jiangsu Hengrui Pharma is 61.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
